Zacks Investment Research downgraded shares of ARKEMA/S (OTCMKTS:ARKAY) from a hold rating to a sell rating in a research report report published on Friday morning, Zacks.com reports.

According to Zacks, “Arkema SA is engaged in the manufacturing and marketing of vinyl products, industrial chemicals, and performance products. Vinyl products include chlorine or caustic soda, pipes and profiles, PVC, and vinyl compounds. Industrial chemicals include emulsion systems, fluorochemicals, hydrogen peroxide, PMMA and methacrylics, specialty acrylic polymers and thiochemicals. Performance products include functional additives, specialty chemicals and technical polymers. The Company’s products can be used for various purposes including air conditioning or refrigeration; chemical processing, coating, construction; packaging; automotive & transportation. Its products, also find their application in adhesives and sealants, agriculture & agrochemicals, consumer goods, electronics, foams, solvents and aerosols market, health, hygiene & beauty, oil & gas, energy, pharmaceuticals, pulp & paper, rubber market, sports & leisure, etc. Arkema SA is headquartered in France. “

A number of other research firms also recently weighed in on ARKAY. Goldman Sachs Group upgraded ARKEMA/S from a sell rating to a buy rating in a research report on Wednesday, March 4th. Barclays downgraded ARKEMA/S from an overweight rating to an equal weight rating in a research report on Thursday, January 16th. ValuEngine downgraded ARKEMA/S from a hold rating to a sell rating in a research report on Thursday, April 2nd. Kepler Capital Markets upgraded ARKEMA/S from a reduce rating to a hold rating in a research report on Tuesday, February 4th. Finally, Morgan Stanley restated an overweight rating on shares of ARKEMA/S in a research report on Monday, March 30th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the company’s stock. ARKEMA/S currently has a consensus rating of Hold and a consensus price target of $119.00.

OTCMKTS:ARKAY opened at $84.92 on Friday. The stock has a fifty day moving average price of $78.43 and a 200-day moving average price of $91.60. The company has a market cap of $6.02 billion, a price-to-earnings ratio of 13.85, a PEG ratio of 2.81 and a beta of 1.55. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.48 and a current ratio of 1.98. ARKEMA/S has a fifty-two week low of $48.89 and a fifty-two week high of $108.19.

ARKEMA/S (OTCMKTS:ARKAY) last released its earnings results on Thursday, February 27th. The basic materials company reported $1.47 earnings per share for the quarter. The firm had revenue of $2.27 billion during the quarter. ARKEMA/S had a return on equity of 10.60% and a net margin of 5.52%. Research analysts predict that ARKEMA/S will post 5.68 EPS for the current fiscal year.

About ARKEMA/S

Arkema SA manufactures and sells specialty chemicals and advanced materials worldwide. It operates through three segments: High Performance Materials, Industrial Specialties, and Coating Solutions. Its products include acrylics, coating resins, electroactive polymers, fluorochemicals, fluoropolymers, functional polyolefins, hydrazine hydrate, hydrogen peroxide, molecular sieves, organic peroxide, oxygenated solvents, poly-ether-ketone-ketone polyetherketoneketone, plastic additives, polymethyl methacrylate resins and sheets, rheology additives, solutions for glass coating, specialty adhesives, specialty polyamides, surfactants and additives, technical fluids, and thiochemicals.

Featured Story: Earnings Per Share

Get a free copy of the Zacks research report on ARKEMA/S (ARKAY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for ARKEMA/S (OTCMKTS:ARKAY)

Receive News & Ratings for ARKEMA/S Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for ARKEMA/S and related companies with MarketBeat.com’s FREE daily email newsletter.

Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here